These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29178667)

  • 1. Comprehensive review of post-organ transplant hematologic cancers.
    Dharnidharka VR
    Am J Transplant; 2018 Mar; 18(3):537-549. PubMed ID: 29178667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation.
    Kinch A; Cavelier L; Bengtsson M; Baecklund E; Enblad G; Backlin C; Thunberg U; Sundström C; Pauksens K
    Am J Transplant; 2014 Dec; 14(12):2838-45. PubMed ID: 25307322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab.
    Rossignol J; Terriou L; Robu D; Willekens C; Hivert B; Pascal L; Guieze R; Trappe R; Baillet C; Huglo D; Morschhauser F
    Am J Transplant; 2015 Jul; 15(7):1976-81. PubMed ID: 25868706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorders.
    Dharnidharka VR; Webster AC; Martinez OM; Preiksaitis JK; Leblond V; Choquet S
    Nat Rev Dis Primers; 2016 Jan; 2():15088. PubMed ID: 27189056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status.
    Poirel HA; Bernheim A; Schneider A; Meddeb M; Choquet S; Leblond V; Charlotte F; Davi F; Canioni D; Macintyre E; Mamzer-Bruneel MF; Hirsch I; Hermine O; Martin A; Cornillet-Lefebvre P; Patey M; Toupance O; Kémény JL; Deteix P; Raphaël M
    Transplantation; 2005 Jul; 80(2):176-84. PubMed ID: 16041261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
    Végso G; Hajdu M; Sebestyén A
    Pathol Oncol Res; 2011 Sep; 17(3):443-54. PubMed ID: 21193979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
    Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
    Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.
    Krisl JC; Doan VP
    Am J Transplant; 2017 Aug; 17(8):1974-1991. PubMed ID: 28394486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer.
    Engels EA
    Am J Transplant; 2019 Dec; 19(12):3223-3232. PubMed ID: 31206226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.
    Preiksaitis JK
    Clin Infect Dis; 2004 Oct; 39(7):1016-23. PubMed ID: 15472855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD30 expression and survival in posttransplant lymphoproliferative disorders.
    Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
    Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
    [No Abstract]   [Full Text] [Related]  

  • 12. Malignancies after pediatric solid organ transplantation.
    Robinson C; Chanchlani R; Kitchlu A
    Pediatr Nephrol; 2021 Aug; 36(8):2279-2291. PubMed ID: 33057766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
    Jagadeesh D; Woda BA; Draper J; Evens AM
    Curr Treat Options Oncol; 2012 Mar; 13(1):122-36. PubMed ID: 22241590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.
    Rosenberg AS; Ruthazer R; Paulus JK; Kent DM; Evens AM; Klein AK
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):684-692.e3. PubMed ID: 27771291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease.
    Ambinder RF
    Recent Results Cancer Res; 2021; 217():197-207. PubMed ID: 33200367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders.
    Tsao L; Hsi ED
    Arch Pathol Lab Med; 2007 Aug; 131(8):1209-18. PubMed ID: 17683183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant malignancy: the role of immunosuppression.
    Penn I
    Drug Saf; 2000 Aug; 23(2):101-13. PubMed ID: 10945373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid Organ Transplantation and Survival among Individuals with a History of Cancer.
    Engels EA; Haber G; Hart A; Lynch CF; Li J; Pawlish KS; Qiao B; Yu KJ; Pfeiffer RM
    Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1312-1319. PubMed ID: 33926864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.